Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
A Phase I, Multicenter, Open-label, Dose Escalation Study of Intravenous Administration of VCN-01 Oncolytic Adenovirus With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
Sponsor: Theriva Biologics SL
A PHASE1 clinical study on Locally Advanced Solid Tumors and Metastatic Solid Tumors, this trial is completed. The trial is conducted by Theriva Biologics SL and has accumulated 14 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Feb 2023 [monthly]
Completed PHASE1
▶ Show 9 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Oct 2019 — Nov 2020 [monthly]
Active Not Recruiting PHASE1
-
Jun 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Oct 2018 — Jun 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Aug 2017 — Feb 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Theriva Biologics SL
For direct contact, visit the study record on ClinicalTrials.gov .